Ramesh narayanan chennai phd
degrader (sard) technology, co-discovered by Narayanan and Duane Miller, Professor Emeritus in the Department of Pharmaceutical Sciences at the uthsc College of Pharmacy. The molecule controls body weight by increasing energy expenditure and body heat, converting white adipose tissue (bad fat) to brown adipose tissue (good energy-burning fat) without increased activity in the form of exercise. Life Insurance, divorce Lawyers, ielts Coaching, mBA Distance. Its one less challenge I have on my hands as a researcher to have to worry about seeking partners for our drugs or filling out applications to protect our discoveries. Narayanan and his lab team have identified a molecule that activates an estrogen receptor and prevents weight gain in mice fed a high-fat diet. 0 / 1000 Characters, find other Advocates Lawyers in Villivakkam. Current therapies seek to block the androgen receptor to prevent its activation. However, sard technology degrades androgen receptors, including those resistant to current therapies, to inhibit tumor growth in patients with advanced prostate cancer. In the absence of clinical trial data, these findings have to be cautiously interpreted,. Narayanan continues to pursue his interests in nuclear receptors and cancer drug discovery at uthsc, where much of his research is funded by GTx. A paper by the team detailing the research was published in the latest online edition of faseb Journal, which is produced by the Federation for American Societies for Experimental Biology. Utrf is already knowledgeable in those areas, says Narayanan. Narayanans lab, one of a small number of labs working on this issue worldwide, is using drugs developed in collaboration with GTx (including sards) and repurposing them to examine their effectiveness in treating different types of breast cancer. Originally from India, Narayanan received his PhD in Molecular Pharmacology from the University of Madras.
Ramesh narayanan chennai phd: Vidyamandir entrance exam sample papers for class 8
Oracle Training, make hadoop Training, he joined uthsc in January 2014 and currently serves as a consultant to GTx for preclinical and clinical projects. And new chemical entities, although the role of androgen receptors in prostate cancer is wellknown. Nearby Location, be the first to review Ramesh Advocate.
Narayanan has published over 40 peer-reviewed research articles and has contributed to about 70 patent applications.Narayanan s research interests are to discover drugs targeting steroid hormone receptor family members and to understand the mechanism of action of therapeutic proteins using chemical biology approach.Ramesh Narayanan, PhD, is an associate professor in the Department of Medicine and Director of the Center for Cancer Drug Discovery at the University.
In 2004, to read more 2embWYA, focusing his research on nuclear hormone receptors and receptor pharmacology in breast cancer and prostate cancer. Narayanan is also grateful for the support he receives from uthsc and his colleagues. He then moved to Houston to serve as a postdoctoral fellow in the Department of Molecular and Cellular Biology at Baylor College of Medicine. Narayanans work with muscular dystrophy focuses on Duchenne muscular dystrophy. Narayanan was hired by Memphisbased biopharmaceutical company GTx as a senior scientist and later named Director of Drug Discovery in 2010. Preclinical models conducted by his lab ramesh showed that androgen receptor activation provided some relief for mice that were severely impaired because of this gene mutation.
Wedding Photographers, wedding Planners, bridal Makeup, marriage Halls.Maids, cleaning Services, child Care, interior Designers, architects.Not so good, just okay, pretty good.